BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

Inclusion Criteria:

* Patients of all genders between 18 and 80 years of age with metastatic pancreatic cancer (unresectable pancreatic cancer with increased levels of cancer antigen 19-9), who had an expected survival time of at least 3 months.

Exclusion Criteria:

Patients fulfilling at least one of the following criteria will be excluded from participation in the study:

* Abnormal liver function classified as total bilirubin \>136 μmol/L (8.0 mg/dL)
* Abnormal kidney function defined by serum creatinine \>120 μmol/L (1.5 mg/dL).
* Abnormal coagulation capacity defined by the relative arbitrary concentration of coagulation factors 2,7,10 \< 0.7 or international normalized ratio \>1.5.
* Verified metastases to the brain.
* Synchronous cancer except for non-melanoma skin cancer and early stage of cervical cancer.
* Abnormal haematology status defined by hemoglobin \< 6.0 g/dL, platelet count \< 100,000/mm\^3 or leucocytes \< 3 x 10\^9/L.
* Clinically significant abnormal ECG.
* Karnofsky performance status score \<60%.
* Pregnancy or breast-feeding.
* Women of fertile age who do not want to be tested for possible pregnancy.
* Uncontrolled bacterial, viral, fungal or parasite infection.
* Under systemic treatment with corticosteroids or other immunosuppressive drugs in the last 21 days before start of the trial treatment.
* Participating in another clinical trial with pharmaceuticals in the last six weeks before start of this trial treatment.
* Not able to understand information.
* Not willing or not able to give written consent to participate in the study.